Institutional members access full text with Ovid®

Share this article on:

Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial

Golubchik, Pavela b; Sever, Jonathana b; Zalsman, Gila b; Weizman, Abrahama b c

International Clinical Psychopharmacology: July 2008 - Volume 23 - Issue 4 - pp 228-231
doi: 10.1097/YIC.0b013e3282f94ae2
Original Articles

Recent studies reported symptomatic overlap between attention deficit/hyperactivity disorder (ADHD) and borderline personality disorder (BPD). Methylphenidate (MPH) is the most efficient treatment for ADHD. We assessed the efficacy and tolerability of MPH treatment in adolescent females who met the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV criteria for both disorders. Fourteen BPD/ADHD female adolescents aged 14–19 years were treated with MPH for 12 weeks, targeting ADHD, BPD symptoms, and aggressive behavior, as rated by ADHD-rating scale (ADHD-RS) and Clinical Global Impression-Severity (CGI-S) scale for BPD and aggressive behavior severity. A significant improvement was detected in both ADHD and BPD severity (baseline vs. end point, ADHD-RS: 33.1±4.8 vs. 17.6±5.2, P<0.001; BPD CGI-S: 4.6±0.8 vs. 3.4±0.8, P<0.0005, respectively) as well as in aggressive behavior (Aggression CGI-S: 3.5±1.3 vs. 1.8±0.5, P<0.001). MPH was well tolerated. MPH may be useful and well tolerated in treating some shared symptoms of ADHD and BPD among female adolescents. Controlled studies are needed to substantiate these findings.

aGeha Mental Health Center, Petah Tikva

bSackler Faculty of Medicine, Tel Aviv University

cLaboratory of Biological Psychiatry, Felsenstein Medical Research Center, Israel

Correspondence to Dr Pavel Golubchik, MD, Child and Adolescent Outpatient Clinic, Geha Mental Health Center, PO Box 102, Petah Tiqva 49100, Israel

Tel: +972 3 9258270; fax: +972 3 9258456; e-mail: pgolubchik@clalit.org.il; aweizman@clalit.org.il

Received 6 September 2007 Accepted 21 January 2008

© 2008 Lippincott Williams & Wilkins, Inc.